A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2017
At a glance
- Drugs CSL 112 (Primary)
- Indications Myocardial ischaemia
- Focus Adverse reactions
- Sponsors CSL Behring
- 07 Jul 2017 Status changed from active, no longer recruiting to completed.
- 05 May 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.